scholarly journals The YKL-40 protein is a potential biomarker for COPD: a meta-analysis and systematic review

2018 ◽  
Vol Volume 13 ◽  
pp. 409-418 ◽  
Author(s):  
Xiang Tong ◽  
Dongguang Wang ◽  
Sitong Liu ◽  
Yao Ma ◽  
Zhenzhen Li ◽  
...  
Keyword(s):  
Systematic Review ◽  
Meta Analysis ◽  
Potential Biomarker

RETRACTED: Potential biomarker for breast cancer screening: A systematic review and meta-analysis

2019 ◽  
Vol 91 ◽  
pp. 518-526 ◽  
Author(s):  
Yurong Wang ◽  
Guijuan Zhang ◽  
Xiaoqian Hao ◽  
Yi Ma ◽  
Min Ma ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Cancer Screening ◽  
Breast Cancer Screening ◽  
Meta Analysis ◽  
Potential Biomarker

P2-247: EEG THETA OSCILLATIONS AS A POTENTIAL BIOMARKER FOR EXECUTIVE DYSFUNCTION IN NEURODEGENERATIVE DISORDERS: A SYSTEMATIC REVIEW WITH META-ANALYSIS

2006 ◽  
Vol 14 (7S_Part_14) ◽  
pp. P768-P768
Author(s):  
Lenka J. Wichmann ◽  
Juan Francisco Flores-Vazquez ◽  
Mengxi Huang ◽  
Ana Luisa Sosa-Ortíz ◽  
André Aleman ◽  
...  
Keyword(s):  
Systematic Review ◽  
Neurodegenerative Disorders ◽  
Meta Analysis ◽  
Executive Dysfunction ◽  
Theta Oscillations ◽  
Potential Biomarker

Circulating tumor cells as a potential biomarker in diagnosis of lung cancer: a systematic review and meta-analysis

2016 ◽  
Vol 12 (2) ◽  
pp. 639-645 ◽  
Author(s):  
Huang Huang ◽  
Yan Shi ◽  
Jietao Huang ◽  
Xiaohui Wang ◽  
Rui Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Systematic Review ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Meta Analysis ◽  
Potential Biomarker ◽  
Diagnosis Of Lung Cancer

scholarly journals The value of miR-155 as a biomarker for the diagnosis and prognosis of lung cancer: a systematic review with meta-analysis

2019 ◽  
Author(s):  
Chuchu Shao ◽  
Fengming Yang ◽  
Zhiqiang Qin ◽  
Xinming Jing ◽  
Yongqian Shu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Systematic Review ◽  
Likelihood Ratio ◽  
Meta Analysis ◽  
Positive Likelihood Ratio ◽  
Disease Free Survival ◽  
Negative Likelihood Ratio ◽  
Free Survival ◽  
Diagnosis And Prognosis ◽  
Potential Biomarker

Abstract Background: Recently, a growing number of studies have reported the coorelation between miR-155 and the diagnosis and prognosis of lung cancer, but results of these researches were still controversial due to insufficient sample size. Thus, we carried out the systematic review and meta-analysis to figure out whether miR-155 could be a screening tool in the detection and prognosis of lung cancer. Methods: A meta-analysis of 13 articles with 19 studies was performed by retrieving the PubMed, Embase and Web of Science. We screened all correlated literaters until December 1st, 2018. For the diagnosis analysis of miR-155 in lung cancer, sensitivity(SEN), specificity (SPE), positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR) and area under the ROC curve (AUC) were pooled to evaluate the accuracy of miRNA-155 in the diagnosis of lung cancer. For the prognosis analysis of miR-155 in lung cancer, the pooled HRs and 95% CIs of miR-155 for overall survival/disease free survival/progression-free survival (OS/DFS/PFS) were calculated. In addition, Subgroup and meta-regression analyses were performed to distinguish the potential sources of heterogeneity between studies. Results: For the diagnostic analysis of miR-155 in lung cancer, the pooled SEN and SPE were 0.82 (95% CI: 0.72-0.88) and 0.78 (95% CI: 0.71-0.84), respectively. Besides, the pooled PLR was 3.75 (95% CI: 2.76-5.10), NLR was 0.23 (95% CI: 0.15-0.37), DOR was 15.99 (95% CI: 8.11-31.52) and AUC was 0.87 (95% CI: 0.84-0.90), indicating a significant value of miR-155 in the lung cancer detection. For the prognostic analysis of miR-155 in lung cancer, up-regulated miRNA-155 expression was not significantly associated with a poor OS (pooled HR = 1.26, 95% CI: 0.66-2.40) or DFS/PFS (pooled HR = 1.28, 95% CI: 0.82-1.97). Conclusions: The present meta-analysis demonstrated that miR-155 could be a potential biomarker for the detection of lung cancer but not an effective biomarker for predicting the outcomes of lung cancer. Furthermore, more well-designed researches with larger cohorts were warranted to confirm the value of miR-155 for the diagnosis and prognosis of lung cancer.

scholarly journals MicroRNA-92a as a Potential Biomarker in Diagnosis of Colorectal Cancer: A Systematic Review and Meta-Analysis

PLoS ONE ◽  
2014 ◽  
Vol 9 (2) ◽  
pp. e88745 ◽  
Author(s):  
Xin Yang ◽  
Zongyue Zeng ◽  
Yixuan Hou ◽  
Taixian Yuan ◽  
Chao Gao ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Systematic Review ◽  
Meta Analysis ◽  
Potential Biomarker

scholarly journals Pentraxin 3 as a promising biomarker for cancer detection: a systematic review and meta-analysis

2019 ◽  
Author(s):  
Qindong Liang ◽  
Guangjie Zhang ◽  
Huaan Huang ◽  
Nai Xing ◽  
Shangchun Sheng ◽  
...  
Keyword(s):  
Systematic Review ◽  
Likelihood Ratio ◽  
Cancer Detection ◽  
Large Scale ◽  
Meta Analysis ◽  
Positive Likelihood Ratio ◽  
Negative Likelihood Ratio ◽  
Cochrane Library ◽  
Pentraxin 3 ◽  
Potential Biomarker

Abstract Background Mounting studies reported that circulating pentraxin 3 (PTX3) expression level was significantly different between cancer patients and healthy groups, suggesting that PTX3 may be a potential biomarker for cancer detection. However, the results were inconsistent. In this paper, a systematic review and meta-analysis was performed to quantitatively assess the diagnostic value of PTX3 in cancer detection.Methods A comprehensive computerized literature search was conducted in Embase, PubMed, Cochrane Library, Web of Science, Chinese National Knowledge Infrastructure (CNKI) from inception to July 31, 2019. Eligible studies were identified and raw data were extracted. Diagnostic estimates were synthesized using STATA (version 12.0) and MetaDisc (version 1.4) statistical software.Results Overall, 9 studies from 8 citations with a total of 1408 cancer patiens and 3116 controls were included in this meta-analysis. The global sensitivity was 0.70 (95% confidence interval (CI): 0.67 – 0.72), and the specificity was 0.77 (95% CI: 0.75 – 0.78). The pooled positive likelihood ratio (PLR), negative likelihood ratio (NLR), and the diagnostic odds ratio (DOR) were 2.86 (95% CI: 2.29 – 3.56), 0.40 (95% CI: 0.32 – 0.50) and 7.38 (95% CI: 5.05 – 10.78), respectively. The merged AUC was 0.80 (95% CI: 0.76 – 0.83).Conclusion The serum PTX3 appears to be a reliable biomarker for cancer detection though large-scale multicenter studies are needed.

scholarly journals The value of miR-155 as a biomarker for the diagnosis and prognosis of lung cancer: a systematic review with meta-analysis

2019 ◽  
Author(s):  
Chuchu Shao ◽  
Fengming Yang ◽  
Zhiqiang Qin ◽  
Xinming Jing ◽  
Yongqian Shu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Systematic Review ◽  
Likelihood Ratio ◽  
Meta Analysis ◽  
Positive Likelihood Ratio ◽  
Disease Free Survival ◽  
Negative Likelihood Ratio ◽  
Free Survival ◽  
Diagnosis And Prognosis ◽  
Potential Biomarker

Abstract Background: Recently, a growing number of studies have reported the coorelation between miR-155 and the diagnosis and prognosis of lung cancer, but results of these researches were still controversial due to insufficient sample size. Thus, we carried out the systematic review and meta-analysis to figure out whether miR-155 could be a screening tool in the detection and prognosis of lung cancer. Methods: A meta-analysis of 13 articles with 19 studies was performed by retrieving the PubMed, Embase and Web of Science. We screened all correlated literaters until December 1st, 2018. For the diagnosis analysis of miR-155 in lung cancer, sensitivity(SEN), specificity (SPE), positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR) and area under the ROC curve (AUC) were pooled to evaluate the accuracy of miRNA-155 in the diagnosis of lung cancer. For the prognosis analysis of miR-155 in lung cancer, the pooled HRs and 95% CIs of miR-155 for overall survival/disease free survival/progression-free survival (OS/DFS/PFS) were calculated. In addition, Subgroup and meta-regression analyses were performed to distinguish the potential sources of heterogeneity between studies. Results: For the diagnostic analysis of miR-155 in lung cancer, the pooled SEN and SPE were 0.82 (95% CI: 0.72-0.88) and 0.78 (95% CI: 0.71-0.84), respectively. Besides, the pooled PLR was 3.75 (95% CI: 2.76-5.10), NLR was 0.23 (95% CI: 0.15-0.37), DOR was 15.99 (95% CI: 8.11-31.52) and AUC was 0.87 (95% CI: 0.84-0.90), indicating a significant value of miR-155 in the lung cancer detection. For the prognostic analysis of miR-155 in lung cancer, up-regulated miRNA-155 expression was not significantly associated with a poor OS (pooled HR = 1.26, 95% CI: 0.66-2.40) or DFS/PFS (pooled HR = 1.28, 95% CI: 0.82-1.97). Conclusions: The present meta-analysis demonstrated that miR-155 could be a potential biomarker for the detection of lung cancer but not an effective biomarker for predicting the outcomes of lung cancer. Furthermore, more well-designed researches with larger cohorts were warranted to confirm the value of miR-155 for the diagnosis and prognosis of lung cancer.

scholarly journals The value of miR-155 as a biomarker for the diagnosis and prognosis of lung cancer: a systematic review with meta-analysis

2019 ◽  
Author(s):  
Chuchu Shao ◽  
Fengming Yang ◽  
Zhiqiang Qin ◽  
Xinming Jing ◽  
Yongqian Shu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Systematic Review ◽  
Meta Analysis ◽  
Diagnostic Value ◽  
Bibliographic Databases ◽  
Diagnosis And Prognosis ◽  
Prognostic Analysis ◽  
Potential Biomarker ◽  
Keywords Lung Cancer ◽  
The Impact

Abstract Abstract Background: In recent years, several studies have investigated the impact of miR-155 on the diagnosis and prognosis of LCa, but results of these researches were still controversial due to insufficient sample size. Thus, we carried out this systematic review and meta-analysis to figure out whether miR-155 could be a screening tool in the detection and prognosis of LCa. Methods: A meta-analysis of 13 articles with 19 studies was performed by retrieving the PubMed, Embase and other bibliographic databases. We screened all correlated literaters until December 1st, 2018. For the diagnostic value of miR-155 in LCa, SEN, SPE, PLR, NLR, DOR and AUC were pooled to evaluate the accuracy of miRNA-155 in the diagnosis of LCa. Subgroup and meta-regression analyses were performed to distinguish the potential sources of heterogeneity between studies. For the prognositic value of miR-155 in LCa, the pooled HRs and 95% CIs of miRNA-155 for OS and DFS/ PFS were calculated. Results: For the diagnosis analysis of miR-155 in LCa, the pooled SEN and SPE were 0.82 (95% CI: 0.72-0.88) and 0.78 (95% CI: 0.71-0.84), respectively. Besides, the pooled PLR was 3.75 (95% CI: 2.76-5.10), NLR was 0.23 (95% CI: 0.15-0.37), DOR was 15.99 (95% CI: 8.11-31.52) and AUC was 0.87 (95% CI: 0.84-0.90), indicating a significant value of miR-155 in the LCa detection. For the prognostic analysis of miR-155 in LCa, up-regulated miRNA-155 expression was not significantly associated with a poor OS (pooled HR = 1.26, 95% CI: 0.66-2.40) or DFS/PFS (pooled HR = 1.28, 95% CI: 0.82-1.97). Conclusions: This meta-analysis demonstrated that miR-155 could be used as a potential biomarker in the diagnosis of LCa but not an effective biomarker for predicting the prognosis of LCa. Furthermore, more well-designed researches with larger cohorts were warranted to confirm the value of miR-155 for the diagnosis and prognosis of LCa. Keywords: lung cancer, miR-155, diagnosis, prognosis, biomarker

Sign in / Sign up

Export Citation Format

Share Document